Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment
Open Access
- 12 January 2021
- journal article
- review article
- Published by Wiley in HemaSphere
- Vol. 5 (2) , e523
Abstract
The aggressive lymphoma, extranodal natural killer/T-cell lymphoma-nasal type, is strongly associated with Epstein-Barr virus (EBV) and is most common in Asia and in South and Central America. By contrast, incidence is low in the United States and Europe, where extranodal natural killer/T-cell lymphoma represents only 0.2%-0.4% of all newly diagnosed non-Hodgkin lymphomas. At diagnosis, it is important to test for EBV DNA in plasma by polymerase chain reaction and to carry out positron emission tomography/computer tomography and magnetic resonance imaging of the nasopharynx. In stage I/II disease, radiotherapy is the most important treatment modality, but in high-risk stage I/II disease (stage II, age > 60 y, elevated lactate dehydrogenase, Eastern Cooperative Oncology Group performance score ≥2, primary tumor invasion), it should be combined with chemotherapy. The most optimal responses are reached with nonmultidrug resistance-based therapy (eg, asparaginase- or platinum-based therapy). Therapeutic approaches consist of either platinum-based concurrent chemoradiotherapy or sequential chemoradiotherapy. The minimum dose of radiotherapy should be 50-56 Gy. Treatment of stage III/IV disease consists of 3 cycles of chemotherapy followed by autologous hematopoietic cell transplantation. Allogeneic hematopoietic cell transplantation should only be considered in case of relapsed disease or after difficulty reaching complete remission. During treatment and follow-up, plasma EBV levels should be monitored as a marker of tumor load.Keywords
This publication has 72 references indexed in Scilit:
- SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study GroupBlood, 2012
- Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell LymphomaCancer Discovery, 2012
- Prospective measurement of Epstein-Barr virus–DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal typeBlood, 2011
- Metabolic Activity Measured by F-18 FDG PET in Natural Killer-Cell Lymphoma Compared to Aggressive B- and T-Cell LymphomasClinical Nuclear Medicine, 2010
- Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211Journal of Clinical Oncology, 2009
- A comparison of radiation treatment plans using IMRT with helical tomotherapy and 3D conformal radiotherapy for nasal natural killer/T-cell lymphomaBritish Journal of Radiology, 2009
- L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literatureAnnals of Oncology, 2008
- Selective apoptosis of natural killer‐cell tumours by l‐asparaginaseBritish Journal of Haematology, 2005
- Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patientsBlood, 2004
- Use of ?-asparaginase in childhood ALLCritical Reviews in Oncology/Hematology, 1998